CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2015—Horizon Discovery Group has signed a supply and commercialization agreement with Thermo Fisher Scientific. Under the terms of the agreement, Thermo Fisher will market and distribute Horizon’s X-MAN human haploid and diploid isogenic cell line collection and will further offer the X-MAN haploid cell line generation service to its worldwide customer base.
The X-MAN cell line range represents an extensive bank of genetically defined human cell lines—models that accurately exhibit disease-causing genetics and have undergone a high degree of validation and quality control. These models help researchers to understand how complex genetic diseases manifest themselves, and can reduce the cost of bringing to market new personalized therapies by streamlining many aspects of drug development, including target identification, target validation, assay development, drug screening, lead optimization, and biomarker-driven clinical trial design.
The X-MAN catalog includes both diploid cell lines and haploid cell lines developed using Horizon’s proprietary precision (rAAV) and high-throughput (HT-CRISPR) genome-editing technologies.
All of the X-MAN cell lines are provided as isogenic pairs, meaning that each modified cell is provided with a matched control so that when experiments are performed, researchers can attribute differences in experimental results to the specific genomic modification.
Horizon Discovery Group, +44 (0)1223 655 580